Skip to main content

Diagnostic and Drug Discovery Initiative for Alzheimer’s Disease

Objective

Alzheimer’s disease (AD) is the major cause of dementia which has no cure at the moment. The overall aim of the work described in this proposal is to create a long-term strategic partnership between Sheffield University (UK), Lisbon University (Portugal), Eli Lilly (UK) and Biofordrug (Italy) in order to develop chemical biology tools for better understanding the role of PrPC in AD and harnessing this understanding to develop novel chemical entities for diagnostic and therapeutics applications.

The D3i4AD project brings together a consortium of groups with internationally-leading expertise from academia and industries in chemistry, molecular design and modelling, biochemistry, diagnostic and drug development. Our proposed programme will lead to major increases in the knowledge and capacity of all consortium members, achieved through significant intersectoral exchange of personnel between the partners over the duration of the project (total 134 person months) and through temporary recruitment of 5 new experienced researchers (total 114 person months). The project will thus underpin a substantial programme of intersectoral knowledge transfer and research training and lead to significant innovation and advances in several areas of basic research as well as diagnostics and therapeutics development. These activities will strongly enhance EU standing and international competitiveness in this extremely challenging and increasingly important technological area.

Field of science

  • /natural sciences/biological sciences/biochemistry
  • /medical and health sciences/basic medicine/neurology/alzheimer

Call for proposal

FP7-PEOPLE-2013-IAPP
See other projects for this call

Funding Scheme

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Coordinator

THE UNIVERSITY OF SHEFFIELD
Address
Firth Court Western Bank
S10 2TN Sheffield
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 009 134,94
Administrative Contact
Andrew King (Mr.)

Participants (4)

Eli Lilly and Company Limited
United Kingdom
EU contribution
€ 290 164,16
Address
Lilly House, Priestley Road
RG24 9NL Basingstoke
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Magnus W.Walter (Dr.)
BIOFORDRUG SRL
Italy
EU contribution
€ 449 415,60
Address
Via Edoardo Orabona 4 Dip Farmaco Chimico Univ Bari
70125 Bari
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Nicola Antonio Colabufo (Prof.)
FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA
Portugal
EU contribution
€ 399 591,50
Address
Campo Grande C5 Piso 3
1749016 Lisboa
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gomes Silvia (Mrs.)
AMORFIX LIFE SCIENCES LTD
Canada
EU contribution
€ 60 591,75
Address
American Drive 3403
M2N 2M6 Mississauga On
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Janet Clennett (Ms.)